Boston Financial Mangement LLC Grows Holdings in Stryker Co. (NYSE:SYK)

Boston Financial Mangement LLC lifted its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 5.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,609 shares of the medical technology company's stock after buying an additional 1,162 shares during the quarter. Boston Financial Mangement LLC's holdings in Stryker were worth $7,780,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Dunhill Financial LLC raised its position in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after acquiring an additional 37 shares during the period. Darwin Wealth Management LLC purchased a new position in Stryker in the 3rd quarter valued at about $36,000. Activest Wealth Management acquired a new stake in Stryker in the 4th quarter worth about $36,000. Crews Bank & Trust acquired a new stake in Stryker in the 4th quarter worth about $39,000. Finally, Hara Capital LLC purchased a new stake in Stryker during the 3rd quarter worth approximately $42,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

SYK has been the topic of a number of research analyst reports. Wells Fargo & Company lifted their price target on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Piper Sandler reaffirmed an "overweight" rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Needham & Company LLC reiterated a "buy" rating and issued a $442.00 target price on shares of Stryker in a research report on Wednesday, January 29th. Morgan Stanley upgraded shares of Stryker from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $370.00 to $445.00 in a research report on Monday, December 2nd. Finally, StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and a consensus price target of $420.68.

Stryker Trading Down 1.0 %

SYK stock traded down $3.82 during mid-day trading on Friday, hitting $382.59. 1,268,413 shares of the company were exchanged, compared to its average volume of 1,388,856. The business has a fifty day simple moving average of $377.92 and a 200-day simple moving average of $368.21. The firm has a market capitalization of $145.99 billion, a P/E ratio of 49.30, a PEG ratio of 2.93 and a beta of 0.96. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the firm posted $3.46 earnings per share. On average, equities research analysts predict that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.